Our early-to-market, clinically researched formulation for Inflammatory Bowel Disease showed more than 2x the reduction in inflammation compared to corticosteroid treatment in human biopsy studies.
PlantEXT is developing all-natural medical skin care products that is the first-generation of topical cannabis medications for treating inflammation. By taking more than a century of organic chemistry experience and combining it with the established anti-inflammatory activity of PlantEXT’s terpene and cannabinoid formulations, PlantEXT is launching efficient products for treating medical conditions including Atopic Dermatitis, Psoriasis and more.
PlantEXT has developed a unique and innovative method of combining all-natural ingredients with CBD and terpenes in order to reduce pain for arthritis and migraine without any drug intervention. As medical cannabis is a well accepted and effective treatment for pain the PlantEXT targeted and unique formulas have been developed in various dosage forms to capture best synergies between active ingredients. The market for natural pain solutions serves an immense opportunity as abuse remains a prevalent and troubling side effect of current pharmaceutical treatments while the market was estimated at $60B USD in 2015 and expected to rise to $83B by 2024.
PlantEXT is honored to be a part of an important and prestigious joint venture that is working on R&D related to the endocannabinoid system and is showing remarkable and exciting potential to treat addiction as a disease. Based on the successful research completed to date, patent applications have been filed in various jurisdictions to protect the use of fatty acid amides in the treatment of addiction disorders and addiction related conditions. This research and development is a collaboration between 4 international leading endocannabinoid system research centers in the United States, Canada, Europe and Israel, coordinated by Professor Raphael Mechoulam, who is also the inventor and the scientific consultant on the project, at The Hebrew University, Jerusalem. For more than 50 years Professor Mechoulam has been a global leader in researching medical cannabis and the human endocannabinoid system. Profession Mechoulam started to focus on cannabis research in the early 1960s and isolated the chemical compounds of cannabis (which he called “cannabinoids”), specifically CBD (the main non-psychoactive component) and THC (the psychoactive component).
PlantEXT has a wealth of proprietary innovation and knowledge that has been the basis of the product pipeline. The PlantEXT partnership and consociation with outstanding academic research institutions guarantees first hand opportunities and knowledge in new technologies and innovations. This leverage guarantees a cutting edge product portfolio pipeline.
2300 Yonge Street, Suite 1709
Toronto, ON
M4P 1E4
Developing and commercializing the most effective, clinically evidenced medical cannabis formulations that improve the quality of life for patients across the globe.
